The Trendlines Group has established two new portfolio companies, Tandem Technologies and Zeev Implants, via its unit Trendlines Medical.
The two new companies bring the total number of Trendlines portfolio companies to 47.
Founded by medtech entrepreneur and chief executive officer, Noam Hassidov, Tandem Technologies aims to make the process of removing and retrieving colon polyps much more efficient and accurate, with the goal of a near 100% retrieval rate.
Trendlines has subscribed a 48.8% fully-diluted share in Tandem Technologies.
Meanwhile, Zeev Implants was founded by Pinchas Kfir, a dental surgeon, lawyer, and experienced businessperson. The company’s modular dental implant technology is intended to solve the most common sources of dental implant problems and diseases, including peri-implant disease, without the need to remove or replace the implant.
Patented in Israel, patents are pending in the United States and Europe. Trendlines has subscribed for a 49.8% fully-diluted share in Zeev Implants.
Shares in Trendlines Group closed 3.28% higher at 31.5 cents on Wednesday.
Click Here To Register For Free Trial Services OR Give A Missed Call : +6531581402 Follow Us On Twitter : www.twitter.com/epicresearchsg Like Us On Facebook : www.facebook.com/EpicResearchSingapore Need Any Assistance Feel Free To Mail Us at : info@epicresearch.sg
The two new companies bring the total number of Trendlines portfolio companies to 47.
Founded by medtech entrepreneur and chief executive officer, Noam Hassidov, Tandem Technologies aims to make the process of removing and retrieving colon polyps much more efficient and accurate, with the goal of a near 100% retrieval rate.
Trendlines has subscribed a 48.8% fully-diluted share in Tandem Technologies.
Meanwhile, Zeev Implants was founded by Pinchas Kfir, a dental surgeon, lawyer, and experienced businessperson. The company’s modular dental implant technology is intended to solve the most common sources of dental implant problems and diseases, including peri-implant disease, without the need to remove or replace the implant.
Patented in Israel, patents are pending in the United States and Europe. Trendlines has subscribed for a 49.8% fully-diluted share in Zeev Implants.
Shares in Trendlines Group closed 3.28% higher at 31.5 cents on Wednesday.
Click Here To Register For Free Trial Services OR Give A Missed Call : +6531581402 Follow Us On Twitter : www.twitter.com/epicresearchsg Like Us On Facebook : www.facebook.com/EpicResearchSingapore Need Any Assistance Feel Free To Mail Us at : info@epicresearch.sg
0 comments:
Post a Comment